169 related articles for article (PubMed ID: 28273185)
1. [Pathogenesis and genetic landscape of acute myeloid leukemia].
Rajnai H; Király AP
Magy Onkol; 2017 Mar; 61(1):21-28. PubMed ID: 28273185
[TBL] [Abstract][Full Text] [Related]
2. Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia.
Higgins A; Shah MV
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32640569
[TBL] [Abstract][Full Text] [Related]
3. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
[TBL] [Abstract][Full Text] [Related]
4. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
[TBL] [Abstract][Full Text] [Related]
5. Clonal Hematopoiesis and therapy related MDS/AML.
Desai P; Roboz GJ
Best Pract Res Clin Haematol; 2019 Mar; 32(1):13-23. PubMed ID: 30927970
[TBL] [Abstract][Full Text] [Related]
6. The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.
Eisfeld AK; Mrózek K; Kohlschmidt J; Nicolet D; Orwick S; Walker CJ; Kroll KW; Blachly JS; Carroll AJ; Kolitz JE; Powell BL; Wang ES; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
Leukemia; 2017 Oct; 31(10):2211-2218. PubMed ID: 28321123
[TBL] [Abstract][Full Text] [Related]
7. Advances in Acute Myeloid Leukemia Genomics, Where Do We Stand in 2018?
Madanat YF; Kalaycio ME; Nazha A
Acta Med Acad; 2019 Apr; 48(1):35-44. PubMed ID: 31264431
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts-de-France AML observatory.
Renaud L; Nibourel O; Marceau-Renaut A; Gruson B; Cambier N; Lionne-Huyghe P; Choufi B; Rodriguez C; Frimat C; Plantier I; Stalnikiewicz L; Bemba M; Berthon C; Marolleau JP; Quesnel B; Preudhomme C; Duployez N
Am J Hematol; 2019 Jan; 94(1):E24-E27. PubMed ID: 30358899
[No Abstract] [Full Text] [Related]
9. The evolving molecular genetic landscape in acute myeloid leukaemia.
Sanders MA; Valk PJ
Curr Opin Hematol; 2013 Mar; 20(2):79-85. PubMed ID: 23380602
[TBL] [Abstract][Full Text] [Related]
10. NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features.
Andersen MT; Andersen MK; Christiansen DH; Pedersen-Bjergaard J
Leukemia; 2008 May; 22(5):951-5. PubMed ID: 18273044
[TBL] [Abstract][Full Text] [Related]
11. When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter.
Roloff GW; Griffiths EA
Blood Adv; 2018 Nov; 2(21):3070-3080. PubMed ID: 30425072
[TBL] [Abstract][Full Text] [Related]
12. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implication of N-RAS gene mutations in Egyptian adult acute myeloid leukemia.
Elghannam DM; Abousamra NK; Shahin DA; Goda EF; Azzam H; Azmy E; El-Din MS; El-Refaei MF
Egypt J Immunol; 2009; 16(1):9-15. PubMed ID: 20726318
[TBL] [Abstract][Full Text] [Related]
14. Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
Martelli MP; Sportoletti P; Tiacci E; Martelli MF; Falini B
Blood Rev; 2013 Jan; 27(1):13-22. PubMed ID: 23261068
[TBL] [Abstract][Full Text] [Related]
15. Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia.
Nebbioso A; Benedetti R; Conte M; Iside C; Altucci L
Expert Opin Ther Targets; 2015; 19(9):1187-202. PubMed ID: 26028314
[TBL] [Abstract][Full Text] [Related]
16. Therapy-related myelodysplastic syndrome/acute myeloid leukemia with del(7)(q22) in a patient with de novo AML.
Kim YG; Cho SY; Park TS; Oh SH; Yoon HJ
Ann Clin Lab Sci; 2011; 41(1):79-83. PubMed ID: 21325260
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and
Martin-Cabrera P; Jeromin S; Perglerovà K; Haferlach C; Kern W; Haferlach T
Haematologica; 2017 Apr; 102(4):e125-e128. PubMed ID: 28057736
[No Abstract] [Full Text] [Related]
18. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
19. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
Kohlmann A; Bacher U; Schnittger S; Haferlach T
Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
[TBL] [Abstract][Full Text] [Related]
20. [Precision medicine for acute myeloid leukemia based on genomic profiling].
Sanada M
Rinsho Ketsueki; 2019; 60(7):847-853. PubMed ID: 31391376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
